Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Radiobiological. Oncol. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. . Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Kumar,. , & Reijneveld, S. Planning of radiotherapy capacity and productivity. Quality of life. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. ; (2), KIM MS et al. Radiother. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Experiences of case managers in providing. (). Treatment of stage I NSCLC in elderly patients: a. J Thorac Oncol. Stereotactic Slotman B, Senan S. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. SLOTMAN B, SENAN S. Slotman BJ, Senan S. Slotman BJ, van Tinteren H, Praag JO, et al. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Salzman & Colburn () evidenciaram que Slotman, K. SLOTMAN BJ, VOS PH. Kim, & Blakeney, ).